{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:34:09Z","timestamp":1790746449376,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T00:00:00Z","timestamp":1673395200000},"content-version":"vor","delay-in-days":2659,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["mp.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Modern Pathology"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1038\/modpathol.2015.93","type":"journal-article","created":{"date-parts":[[2015,8,14]],"date-time":"2015-08-14T07:41:09Z","timestamp":1439538069000},"page":"1315-1323","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"title":["Recombinant interferon-\u03b1 in myelofibrosis reduces bone marrow fibrosis, improves its morphology and is associated with clinical response"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4006-7317","authenticated-orcid":false,"given":"Marco","family":"Pizzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard T","family":"Silver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariella","family":"Barel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attilio","family":"Orazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/modpathol.2015.93_bib1","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","first-page":"18","author":"Vardiman","year":"2008"},{"key":"10.1038\/modpathol.2015.93_bib2","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/sj.leu.2404955","article-title":"Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms","volume":"22","author":"Tefferi","year":"2008","journal-title":"Leukemia"},{"key":"10.1038\/modpathol.2015.93_bib3","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.clml.2014.11.002","article-title":"Impact of bone marrow pathology on the clinical management of Philadelphia chromosome-negative myeloproliferative neoplasms","volume":"15","author":"Pozdnyakova","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1038\/modpathol.2015.93_bib4","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.3324\/haematol.2013.086348","article-title":"Advances in myelofibrosis: a clinical case approach","volume":"98","author":"Mascarenhas","year":"2013","journal-title":"Haematologica"},{"key":"10.1038\/modpathol.2015.93_bib5","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrc2210","article-title":"Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders","volume":"7","author":"Levine","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1038\/modpathol.2015.93_bib6","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2","volume":"369","author":"Nangalia","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1038\/modpathol.2015.93_bib7","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","article-title":"New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment","volume":"113","author":"Cervantes","year":"2009","journal-title":"Blood"},{"key":"10.1038\/modpathol.2015.93_bib8","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1200\/JCO.2012.42.0240","article-title":"Improving survival trends in primary myelofibrosis: an international study","volume":"30","author":"Cervantes","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1038\/modpathol.2015.93_bib9","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1182\/blood-2014-07-575373","article-title":"How I treat myelofibrosis","volume":"124","author":"Cervantes","year":"2014","journal-title":"Blood"},{"key":"10.1038\/modpathol.2015.93_bib10","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1182\/blood-2013-12-544411","article-title":"Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts","volume":"123","author":"Passamonti","year":"2014","journal-title":"Blood"},{"key":"10.1038\/modpathol.2015.93_bib11","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1182\/blood-2014-02-558015","article-title":"JAK2 inhibitors do not affect stem cells present in the spleens of patients with myelofibrosis","volume":"124","author":"Wang","year":"2014","journal-title":"Blood"},{"key":"10.1038\/modpathol.2015.93_bib12","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1182\/blood-2013-02-485888","article-title":"Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis","volume":"122","author":"Cervantes","year":"2013","journal-title":"Blood"},{"key":"10.1038\/modpathol.2015.93_bib13","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1586\/ehm.12.69","article-title":"Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis","volume":"6","author":"Silver","year":"2013","journal-title":"Expert Rev Hematol"},{"key":"10.1038\/modpathol.2015.93_bib14","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1182\/blood-2012-07-442012","article-title":"Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon alpha-2a","volume":"122","author":"Quintas-Cardama","year":"2013","journal-title":"Blood"},{"key":"10.1038\/modpathol.2015.93_bib15","doi-asserted-by":"crossref","first-page":"6669","DOI":"10.1182\/blood-2010-11-320069","article-title":"Recombinant interferon-alpha may retard progression of early primary myelofibrosis: a preliminary report","volume":"117","author":"Silver","year":"2011","journal-title":"Blood"},{"key":"10.1038\/modpathol.2015.93_bib16","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1038\/leu.2009.90","article-title":"Recombinant interferon alpha (rIFN alpha-2b) may retard progression of early primary myelofibrosis","volume":"23","author":"Silver","year":"2009","journal-title":"Leukemia"},{"key":"10.1038\/modpathol.2015.93_bib17","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/bjh.12459","article-title":"Efficacy and safety of pegylated-interferon \u03b1-2a in myelofibrosis: a study by the FIM and GEM French cooperative groups","volume":"162","author":"Ianotto","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1038\/modpathol.2015.93_bib18","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.leukres.2013.06.012","article-title":"Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha","volume":"37","author":"Stauffer Larsen","year":"2013","journal-title":"Leuk Res"},{"key":"10.1038\/modpathol.2015.93_bib19","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1182\/asheducation.V2012.1.567.3806899","article-title":"Is there a role for the use of IFN-\u03b1 in primary myelofibrosis?","volume":"2012","author":"Nguyen","year":"2012","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1038\/modpathol.2015.93_bib20","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1182\/blood-2013-03-488098","article-title":"International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report","volume":"122","author":"Tefferi","year":"2013","journal-title":"Blood"},{"key":"10.1038\/modpathol.2015.93_bib21","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.1182\/blood-2014-05-577635","article-title":"Therapy for myeloproliferative neoplasms: when, which agent, and how?","volume":"124","author":"Geyer","year":"2014","journal-title":"Blood"},{"key":"10.1038\/modpathol.2015.93_bib22","first-page":"10","article-title":"Interferon-alpha-induced morphological changes of megakaryocytes: a histomorphometrical study on bone marrow biopsies in chronic myeloproliferative disorders with excessive thrombocytosis","volume":"74","author":"Chott","year":"1990","journal-title":"Br J Haematol"},{"key":"10.1038\/modpathol.2015.93_bib23","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/cncr.11486","article-title":"Phase II study of alpha2 interferon in the treatment of the chronic myeloproliferative disorders (E5487): a trial of the Eastern Cooperative Oncology Group","volume":"98","author":"Radin","year":"2003","journal-title":"Cancer"},{"key":"10.1038\/modpathol.2015.93_bib24","first-page":"498","article-title":"Alpha interferon treatment of idiopathic myelofibrosis","volume":"101","author":"Cervantes","year":"1993","journal-title":"Med Clin (Barc)"},{"key":"10.1038\/modpathol.2015.93_bib25","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1182\/blood.V96.4.1342","article-title":"Pathologic interaction between megakaryocytes and polymorphonuclear leukocytes in myelofibrosis","volume":"96","author":"Schmitt","year":"2000","journal-title":"Blood"},{"key":"10.1038\/modpathol.2015.93_bib26","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1182\/blood-2004-01-0193","article-title":"Increased and pathologic emperipolesis of neutrophils within megakaryocytes associated with marrow fibrosis in GATA-1(low) mice","volume":"104","author":"Centurione","year":"2004","journal-title":"Blood"},{"key":"10.1038\/modpathol.2015.93_bib27","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1017\/S1462399411002043","article-title":"Normal and malignant megakaryopoiesis","volume":"13","author":"Wen","year":"2011","journal-title":"Expert Rev Mol Med"},{"key":"10.1038\/modpathol.2015.93_bib28","first-page":"27","article-title":"Human megakaryocytopoiesis","volume":"23","author":"Gewirtz","year":"1986","journal-title":"Semin Hematol"},{"key":"10.1038\/modpathol.2015.93_bib29","doi-asserted-by":"crossref","first-page":"3692","DOI":"10.1182\/blood-2012-05-432989","article-title":"Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-alpha in a murine model of polycythemia vera","volume":"121","author":"Mullally","year":"2013","journal-title":"Blood"},{"key":"10.1038\/modpathol.2015.93_bib30","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1089\/jir.2012.0120","article-title":"Biological rationale and clinical use of interferon in the classical BCR-ABL-negative myeloproliferative neoplasms","volume":"33","author":"Stein","year":"2013","journal-title":"J Interferon Cytokine Res"},{"key":"10.1038\/modpathol.2015.93_bib31","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.cyto.2015.02.007","article-title":"B cells responses and cytokine production are regulated by their immune microenvironment","volume":"74","author":"Vazquez","year":"2015","journal-title":"Cytokine"},{"key":"10.1038\/modpathol.2015.93_bib32","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1200\/JCO.2010.32.9490","article-title":"Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independ- ently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study","volume":"29","author":"Tefferi","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1038\/modpathol.2015.93_bib33","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1158\/2159-8290.CD-14-0736","article-title":"JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response","volume":"5","author":"Kleppe","year":"2015","journal-title":"Cancer Discov"},{"key":"10.1038\/modpathol.2015.93_bib34","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/leu.2014.3","article-title":"CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"}],"container-title":["Modern Pathology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/modpathol201593.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/modpathol201593","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395222013631?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395222013631?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/modpathol201593.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T00:48:25Z","timestamp":1760230105000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0893395222013631"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":34,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["S0893395222013631"],"URL":"https:\/\/doi.org\/10.1038\/modpathol.2015.93","relation":{},"ISSN":["0893-3952"],"issn-type":[{"value":"0893-3952","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recombinant interferon-\u03b1 in myelofibrosis reduces bone marrow fibrosis, improves its morphology and is associated with clinical response","name":"articletitle","label":"Article Title"},{"value":"Modern Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1038\/modpathol.2015.93","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2015 United States & Canadian Academy of Pathology.","name":"copyright","label":"Copyright"}]}}